Pipeline D

Follicle Induction Technology

🔬 探索性

From repair to regeneration--the first "from-scratch" aesthetic technology

All current aesthetic medicine is "repairing existing"--drugs save dying follicles, transplants relocate surviving ones. Follicle induction breaks through this ceiling: using WNT10B+FGF9+Noggin+RSPO1+SHH-N five-factor combination to induce new follicle morphogenesis on follicle-free skin. DiVo does computational pipeline design and IP licensing (ARM model), no wet-lab, no clinical trials.

High Hairline / Hair Loss

Understand follicle induction principles and progress--read "High Hairline ≠ Hair Loss" and "Five-Factor Cocktail" below.

Aesthetic/Transplant Clinics / Biotech

Evaluate follicle induction computing pipeline capability--focus on "5-Step Pipeline", "Five-Factor Combination", "ARM Partnership Model".

Investors / Peers

Evaluate follicle induction sector barriers--focus on "Differentiation", "Honest Boundaries", "Competitive Landscape".

To Those Concerned About Hairline

If you simply have a naturally high hairline (not hair loss), existing drugs are ineffective for you--because drugs can only save dying follicles, not create non-existent ones. Hairstyling is the most pragmatic current option; transplant after 18 is an alternative. Follicle induction is a decade-away hope--it will be the first to achieve "from-scratch" hair regeneration, but is still in the lab stage, not available for individuals.

High Hairline ≠ Hair Loss

Naturally high hairline and androgenetic alopecia (AGA) are two completely different problems. AGA is DHT attacking follicles causing miniaturization->death, reversible with dutasteride+minoxidil. But naturally high hairline means embryonic follicle development boundary was set further back--that area simply has no follicles, drugs are powerless.

Follicle induction solves this second problem: restarting embryonic follicle morphogenesis programs on skin that has never grown follicles. This requires precise signaling factor combinations--WNT10B initiates, FGF9 condenses dermal papilla, Noggin removes BMP inhibition, RSPO1 amplifies WNT signaling, SHH guides morphogenesis--five factors synergize with temporal regulation to "awaken" follicle neogenesis on adult skin.

Why Existing Drugs Are Ineffective

Drugs (dutasteride/minoxidil) target "saving dying follicles"--inhibiting DHT or activating dermal papilla signaling. But naturally high hairline areas have no follicles to save, like watering land with no seeds--no amount of water grows crops.

Why Follicle Induction Could Be the Endgame

Transplants "relocate"--taking follicles from the back to the front. Follicle induction "creates"--restarting embryonic hair morphogenesis programs in follicle-free areas. If successful, it would overturn the transplant industry's fundamental logic.

DiVo Gen²AI's Role

Follicle induction is the flagship direction of DiVo's "Ageless Beauty" system Pipeline D, and the key leap from "repair" to "regeneration". We only do computational pipeline design and IP licensing--isomorphic with the chip business (ARM model: design only, no manufacturing). Protein factor sequence design, structure optimization, stability assessment, immunogenicity pre-screening, and mRNA delivery design are all done by us; wet-lab (expression/purification/animal/clinical) is delegated to partner CDMO/CRO/hospitals.

We do not do wet-lab, clinical trials, GMP manufacturing, or guarantee in-vivo efficacy. Follicle induction efficacy on human skin has not been validated by any team--this is frontier exploration, but our computational pipeline is deliverable.

Core Capability · Pipeline D · 5-Step Pipeline

From factor structure to mRNA delivery plan · Core engine verified, 4/5 steps available

Step D1Factor structure predictionProtenix V2 + Chai-1 cross-validationWNT10B/FGF9/Noggin/RSPO1/SHH-N 3D structure + interface✓ 已验证

Step D2Engineered protein designPXDesign + ProteinMPNN + LigandMPNNFc fusion/bifunctional fusion/receptor selectivity mutants/stability variants✓ 已验证

Step D3Stability + binding assessmentPro-Prime + ProSST + Protenix V2 co-folding + IPSAEΔΔG + ipSAE + pDockQ stability + binding✓ 已验证

Step D4Immunogenicity + safety assessmentMHCflurry + NetMHCpan/IIpan + BepiPred-2.0 + pVACtoolsImmunogenicity pre-screening + B-cell epitopes + comprehensive safety report✓ 已验证

Step D5mRNA delivery designGEMORNA + RNALens + UTRGANmRNA sequence + stability + UTR optimization + temporal expression plan🔬 探索性

Five-Factor Cocktail

WNT10B + FGF9 + Noggin + RSPO1 + SHH-N - precise combination + temporal regulation = follicle neogenesis

WNT10B-> Master switch for follicle genesis

Target: FZD/LRP5/6

Engineering: Fc fusion extends half-life; RSPO1 co-delivery enhances signaling

FGF9-> Dermal papilla-epithelial signaling bridge

Target: FGFR3c

Engineering: PEGylation extends half-life; receptor selectivity mutants

Noggin-> BMP antagonist

Target: BMP2/4/6

Engineering: Bifunctional fusion protein design with WNT10B

RSPO1-> WNT signal amplifier

Target: ZNRF3/RNF43

Engineering: Stability mutants; co-loaded LNP with WNT10B

SHH-N-> Upstream morphogenesis signal

Target: Patched/Smoothened

Engineering: Cholesterol modification enhances membrane affinity

Key principle: Factor combination requires temporal regulation--WNT initiates first, FGF9 follows to promote condensation, Noggin maintains BMP inhibition throughout. Not all poured in at once, but released in stages.

Differentiation

Core differences from traditional CRO/pharma single-factor experimental trial-and-error

Five-Factor Combination Optimization (World-First Computing Pipeline)

Not single-factor experimental trial-and-error, but using a computing pipeline to jointly optimize WNT10B+FGF9+Noggin+RSPO1+SHH-N concentration ratios, temporal release, and engineered variants--compressing wet-lab workload by orders of magnitude.

ARM

ARM Model: Design Only, No Manufacturing

Isomorphic with the chip business--computing pipeline design + IP licensing, no wet-lab, no clinical trials, no factories. Low risk, high profit, asset-light. Partner CDMO/CRO/hospitals execute validation and clinical trials.

IMM

Design-Stage Immunogenicity Pre-screening

Traditional CROs discover immunogenicity issues at clinical stage. We use MHCflurry+NetMHCpan/IIpan for MHC-I/II pan-allele scanning at Step D4--eliminating high-risk candidates at the design stage.

Three-Phase Roadmap

From diagnosis to clinical--ARM model, design only, no manufacturing

Phase 1

Ageless Diagnosis

✓ 已验证0-6 months

GBP-follicle potential assessment: WGS data -> WNT/SHH pathway genotype -> follicle density PRS -> intervention suggestions

¥500-2,000/case

Phase 2

Factor Combination Optimization

◎ 前瞻概念6-24 months

FollicleX™ computational design service: five-factor cocktail sequence + structure + affinity + immunogenicity + delivery plan

¥100K-500K/project

Phase 3

Clinical Validation Partnership

◎ 前瞻概念2-4 years

FollicleX™ clinical plan package: GMP protein + delivery system + clinical design -> partner hospital execution

IP licensing + milestones

Benchmarks

Core computing engine verified, 4/5 steps available; mRNA delivery design pending end-to-end testing

Metric	Value	Note
Protenix V2 pLDDT	95.4	Factor protein structure prediction accuracy
BoltzGen 5 weights	7.9G complete	All-atom diffusion design + affinity prediction (boltz2_aff 529M params)
ProteinMPNN recovery	>52%	Engineered protein design
Pro-Prime ΔΔG	SOTA	Replaces FoldX as primary stability prediction tool
MHCflurry AUROC	0.7547	Immunogenicity pre-screening (TESLA benchmark)
Factor PDB coverage	5/5	WNT10B/FGF9/Noggin/RSPO1/SHH-N
Pipeline status	exploratory	4/5 steps verified, mRNA delivery design pending end-to-end test
mRNA delivery design	GEMORNA ready	GEMORNA+RNALens+UTRGAN trio deployed

Honest Boundaries

What we can and cannot do, clearly stated--core engine verified, in-vivo efficacy pending partner validation

What We Can Do

✓WNT10B/FGF9/Noggin/RSPO1/SHH-N 3D structure prediction (Protenix V2 pLDDT>90)

✓Engineered protein design (PXDesign+ProteinMPNN+LigandMPNN deployed)

✓Stability assessment (Pro-Prime+ProSST SOTA, replaces FoldX)

✓Binding assessment (Protenix V2 co-folding + IPSAE)

✓Design-stage immunogenicity pre-screening (MHCflurry+NetMHCpan/IIpan+BepiPred-2.0)

✓mRNA delivery design (GEMORNA+RNALens+UTRGAN trio deployed)

✓GBP-follicle potential assessment module (WNT/SHH pathway genotype + follicle density PRS)

✓Chinese population WNT/SHH pathway genotype frequency calibration

What We Don't Do

✗No wet-lab (factor expression/purification/animal experiments delegated to partners)

✗No clinical trials (only design clinical plans, do not execute)

✗No in-vivo efficacy guarantee (computational screening ≠ in-vivo efficacy, requires clinical validation)

✗No GMP manufacturing (only provide sequences + QC standards)

✗DiVoPPIHead affinity prediction architecture complete, pending PDBbind training (currently using pDockQ+ipTM)

✗Follicle induction efficacy on human skin not validated by any team--frontier exploration

Glossary

7 core terms in follicle induction

Abbr.	Full Name	Translation	Explanation
Follicle Induction	Hair Follicle Neogenesis	Creating new follicles on follicle-free skin	Completely different from "saving dying follicles"--starting follicle morphogenesis from scratch, requiring precise signaling factor combinations and temporal regulation
WNT10B	Wingless-type MMTV integration site family member 10B	WNT signaling pathway member 10B	Core master switch protein for follicle genesis, activates β-catenin nuclear entry to initiate follicle gene programs
Dermal Papilla	Dermal Papilla	Dermal Papilla	A cluster of mesenchymal cells at the follicle base, the "command center" for follicle growth; FGF9 induces their condensation
Noggin	Noggin	Noggin (BMP antagonist)	Binds and inhibits BMP2/4/6, removing BMP's block on follicle genesis, allowing WNT signaling to fully act
SHH	Sonic Hedgehog	Sonic Hedgehog	Key signaling protein for embryonic morphogenesis, initiates epithelial-mesenchymal dialogue in follicle genesis
ARM Model	ARM IP Licensing Model	IP Licensing Model	Design only, no manufacturing--same business model as ARM chip company: design architecture -> license -> collect royalties
Melanophagy	Melanophagy	Melanophagy	Melanosome degradation via autophagy by lysosomes, the core mechanism of skin depigmentation